Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
nexi-001 t cells (2 trials)
cyclophosphamide (cytoxan) (1 trial)
fludarabine (fludara) (1 trial)
nexi-003 t cells (1 trial)
Leukemia, Myeloid, Acute (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Trials (3 total)
Trial APIs (4 total)